Articles

PARP inhibition and prostate cancer

BJMO - volume 15, issue 4, june 2021

L. Dirix MD

SUMMARY

Deoxyribonucleic acid (DNA) recombination between homologous chromosomes is essential in the process of meiosis as it drives genetic diversity and assures accurate segregation. In somatic cells, a substantial machinery is involved in DNA damage repair (DDR). Failure to repair DNA damage has many consequences, including cancer predisposition. Insights in DDR mechanisms and the prevalence of defects in DDR in tumours has resulted in the fundamental insight of the presence of DDR defects as a chemosensitising biomarker for alkylating agents in high-grade serous ovarian cancer, non-small-cell lung cancer and glioblastoma. Increasing the DDR defect by PARP inhibition in this context of pre-existing DDR impairment, can result in catastrophic DNA damage and cancer cell death. In patients with mCRPC and demonstrated intratumoural DDR defect, PARP inhibition represents a valuable new treatment option.

(BELG J MED ONCOL 2021;15(4):164-9)

Read more

What you should not have missed in 2017

BJMO - 12, issue 3, february 2018

L. Dirix MD

It has become a yearly tradition during the annual BSMO meeting to have a presentation by Dr Luc Dirix discussing the top stories in oncology over the past year. The 2018 edition was no exception.

Read more

O.03 DETECTION OF AR PERTURBATIONS IN CIRCULATING TUMOUR CELLS AND CELL-FREE DNA FROM PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREDICTS RESISTANCE TO ENDOCRINE THERAPY

BJMO - 12, issue 3, february 2018

B. De Laere PhD, Markus Mayrhofer , T. Whitington , P-J. Van Dam MD, P. Van Oyen , C. Ghysel , J. Ampe , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , Nick Beije , Inge De Kruijff , S. Oeyen , A. Rutten MD, V. Van Dam , A. Brouwer , D. Goossens , Lien Heyrman , G. Van Den Eynden MD, PhD, J. Vandebroek , Jurgen Del-Favero , S. Sleijfer , A. Uhlen , Jeffrey Yachnin , S. Van Laere PhD, Henrik Grönberg , Johan Lindberg , L. Dirix MD

Read more

O.01 Circulating Tumour Cells and Survival in Abiraterone- and Enzalutamide-treated Patients with Castration-Resistant Prostate Cancer

BJMO - 2017, issue 3, february 2017

B. De Laere PhD, P. Van Oyen , C. Ghysel , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , J. Ampe , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , S. Oeyen , V. Van Dam , A. Brouwer , G. Van Den Eynden MD, PhD, A. Rutten MD, J. Vandebroek , S. Van Laere PhD, L. Dirix MD

Read more

O.07 Mutational Landscaping of Liver Metastases with Desmoplastic and Replacement Growth Patterns

BJMO - 2017, issue 3, february 2017

P-J. Van Dam MD, B. Galjart , P. De Paepe MD, PhD, T. Feryn , V. Duwel , L. Dirix MD, P. Vermeulen , S. Van Laere PhD

Read more

O.08 Evaluation of HER2 expression and amplification in CTCs using CellSearch immunofluorescence and FISH

BJMO - 2017, issue 3, february 2017

A. Brouwer , P-J. Van Dam MD, E. Sluydts , M. Peeters MD, PhD, P. Vermeulen , S. Van Laere PhD, L. Dirix MD

Read more

P.15 Abiraterone acetate associated rhabdomyolysis

BJMO - 2017, issue 3, february 2017

B. Van den Heuvel MD, H. Celen , L. Dirix MD, J. Vandebroeck , A. Rutten MD

Read more
X